Seres Therapeutics Inc. [NASDAQ: MCRB] gained 7.28% or 1.95 points to close at $28.74 with a heavy trading volume of 1021239 shares.
It opened the trading session at $26.90, the shares rose to $29.46 and dropped to $26.50, the range by which the price of stock traded the whole day. The daily chart for MCRB points out that the company has recorded 705.04% gains over the past six months. However, it is still -1040.48% lower than its most recent low trading price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
If we look at the average trading volume of 2.96M shares, MCRB reached to a volume of 1021239 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Seres Therapeutics Inc. [MCRB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MCRB shares is $33.21 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MCRB stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for Seres Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 18, 2020. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on August 18, 2020, representing the official price target for Seres Therapeutics Inc. stock. Previously, the target price had yet another raise from $4 to $29, while Jefferies kept a Buy rating on MCRB stock. On August 11, 2020, analysts increased their price target for MCRB shares from 8 to 41.
The Average True Range (ATR) for Seres Therapeutics Inc. is set at 1.75, with the Price to Sales ratio for MCRB stock in the period of the last 12 months amounting to 83.56.
Trading performance analysis for MCRB stock
Seres Therapeutics Inc. [MCRB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.49. With this latest performance, MCRB shares gained by 17.40% in over the last four-week period, additionally plugging by 705.04% over the last 6 months – not to mention a rise of 616.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MCRB stock in for the last two-week period is set at 70.91, with the RSI for the last a single of trading hit 70.67, and the three-weeks RSI is set at 68.10 for Seres Therapeutics Inc. [MCRB]. The present Moving Average for the last 50 days of trading for this stock 19.45, while it was recorded at 26.52 for the last single week of trading, and 7.85 for the last 200 days.
Seres Therapeutics Inc. [MCRB]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Seres Therapeutics Inc. [MCRB] shares currently have an operating margin of -203.98. Seres Therapeutics Inc.’s Net Margin is presently recorded at -203.68.
Reflecting on the efficiency of the workforce at the company, Seres Therapeutics Inc. [MCRB] managed to generate an average of -$650,731 per employee. Receivables Turnover for the company is 38.66 with a Total Asset Turnover recorded at a value of 0.27.Seres Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60.
Seres Therapeutics Inc. [MCRB]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Seres Therapeutics Inc. posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.32/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 28.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MCRB.
An analysis of insider ownership at Seres Therapeutics Inc. [MCRB]
There are presently around $2,075 million, or 73.90% of MCRB stock, in the hands of institutional investors. The top three institutional holders of MCRB stocks are: FLAGSHIP PIONEERING INC. with ownership of 21,571,764, which is approximately 0% of the company’s market cap and around 10.00% of the total institutional ownership; ARK INVESTMENT MANAGEMENT LLC, holding 12,478,934 shares of the stock with an approximate value of $358.64 million in MCRB stocks shares; and NIKKO ASSET MANAGEMENT AMERICAS, INC., currently with $212.68 million in MCRB stock with ownership of nearly -12.094% of the company’s market capitalization.
Positions in Seres Therapeutics Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 62 institutional holders increased their position in Seres Therapeutics Inc. [NASDAQ:MCRB] by around 7,062,322 shares. Additionally, 21 investors decreased positions by around 2,797,604 shares, while 17 investors held positions by with 62,356,350 shares. The mentioned changes placed institutional holdings at 72,216,276 shares, according to the latest SEC report filing. MCRB stock had 22 new institutional investments in for a total of 751,241 shares, while 6 institutional investors sold positions of 117,361 shares during the same period.